Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...
Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...
The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...
Altitude Labs, a biotechnology accelerator backed by Recursion Pharmaceuticals, on Wednesday said it is launching a new fund to give pre-seed grants to life sciences researchers and startups disrupted ...
The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...
Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果